Neoatricon (dopamine hydrochloride)
- Region
- 🇪🇺 EU
- Active substance
- dopamine hydrochloride
- Company
- BrePco Biopharma Limited
- Status
- Authorised
- Therapeutic area
- Hypotension
- CHMP opinion
- Thu 21 Mar 2024
- EU approval
- Mon 27 May 2024
- Application
- EMEA/H/C/006044
- ATC
- C01CA04
- Official record
- www.ema.europa.eu
Indication
Treatment of hypotension in haemodynamically unstable neonates, infants and children < 18 years
Regulatory milestones
No milestones recorded in the last year.
Follow Neoatricon
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.